TLR-Modulating Small Molecules for Balanced Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants and immunomodulatory strategies face limitations such as toxicity, limited effectiveness, and difficulty in formulation, and there is a need for more effective treatments for inflammatory and immune-related disorders like ARDS, BPD, acne, psoriasis, and lung cancer.
Innovation Solution
Development of novel carbohydrate-derived Toll-like Receptor (TLR) modulating small molecules that act as agonists or antagonists to balance Th1 and Th2 cytokine production, reduce inflammatory cytokines, and stimulate or inhibit immune responses as needed, formulated into compositions for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccine adjuvants are used, then immune response is stimulated, but toxicity and limited effectiveness occur
Solution Approach 1:
The patent modifies the chemical structure of lipid A by changing parameters such as the degree of phosphorylation, acylation patterns, and sugar chain composition to create derivatives with improved safety profiles while maintaining immunostimulatory activity. This allows tuning the balance between efficacy and toxicity.
Solution Approach 2:
The patent employs biodegradable carbohydrate-based structures that are metabolized by the body after fulfilling their immunomodulatory function, avoiding accumulation and long-term toxicity associated with conventional adjuvants.
2Reliability
If current immunomodulatory strategies are applied, then immune response is modulated, but formulation difficulty arises
Solution Approach 1:
The carbohydrate-derived TLR modulators are designed to work across multiple administration routes (parenteral, inhalation, topical) and for various indications (vaccines, inflammatory diseases, cancer), eliminating the need for separate formulations for different applications.
Solution Approach 2:
By adjusting molecular parameters such as hydrophilicity, molecular weight, and functional group composition, the patent creates derivatives with optimized pharmacokinetic properties for different routes of administration, simplifying formulation development.
3Reliability
If TLR agonists are used to stimulate immune response, then Th1 and Th2 cytokine production increases, but inflammatory cytokine levels rise causing tissue injury
Solution Approach 1:
The patent employs TLR modulators that can dynamically switch between agonist and antagonist activities based on local immune conditions, cytokine profiles, and disease state, allowing the immune response to be amplified when needed while preventing excessive inflammation.
Solution Approach 2:
The carbohydrate-derived molecules act as intermediaries that engage TLRs to initiate controlled immune signaling, producing a balanced cytokine profile that achieves protective immunity without the uncontrolled inflammation caused by conventional agonists.
Data Source
AI summary
The present invention includes novel compositions and methods for treating comprising a compound with the Formula I:wherein n=0, 1, 2, 3, 4, or 5; X=NH or O or S; Y=phenyl, or a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R=H, C(O)R2, SO2R2; R1=H, C(O)R2, SO2R2; R2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4; R3, R4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl, and Z=NH, or O, or none, and optionally wherein both X and Z are not both S, and wherein the amount of the compound is selected to either inhibit or activate the immune response.